BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19596060)

  • 1. Embryonic stem cell-derived cardiomyocytes as a model system to study cardioprotective effects of dexamethasone in doxorubicin cardiotoxicity.
    Farokhpour M; Karbalaie K; Tanhaei S; Nematollahi M; Etebari M; Sadeghi HM; Nasr-Esfahani MH; Baharvand H
    Toxicol In Vitro; 2009 Oct; 23(7):1422-8. PubMed ID: 19596060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of dexamethasone administration on the protection against doxorubicin-induced cardiotoxicity in purified embryonic stem cell-derived cardiomyocytes.
    Dehghani L; Farokhpour M; Karbalaie K; Nematollahi M; Tanhaie S; Hayati-Rodbari N; Kiani-Esfahani A; Hescheler J; Nasr-Esfahani MH; Baharvand H
    Tissue Cell; 2013 Apr; 45(2):101-6. PubMed ID: 23141520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of developing cardiomyocytes from recombinant murine embryonic stem cells reveals regulation of transcription factor clusters.
    Seewald MJ; Ellinghaus P; Kassner A; Stork I; Barg M; Niebrügge S; Golz S; Summer H; Zweigerdt R; Schräder EM; Feicht S; Jaquet K; Reis S; Körfer R; Milting H
    Physiol Genomics; 2009 Jun; 38(1):7-15. PubMed ID: 19293330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach.
    Sartiani L; Bettiol E; Stillitano F; Mugelli A; Cerbai E; Jaconi ME
    Stem Cells; 2007 May; 25(5):1136-44. PubMed ID: 17255522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions--a comparison of multiple cell lines.
    Pekkanen-Mattila M; Kerkelä E; Tanskanen JM; Pietilä M; Pelto-Huikko M; Hyttinen J; Skottman H; Suuronen R; Aalto-Setälä K
    Ann Med; 2009; 41(5):360-70. PubMed ID: 19165643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
    Sun X; Zhou Z; Kang YJ
    Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiomyocyte resistance to doxorubicin mediated by A(3) adenosine receptor.
    Shneyvays V; Mamedova LK; Korkus A; Shainberg A
    J Mol Cell Cardiol; 2002 May; 34(5):493-507. PubMed ID: 12056854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
    Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
    Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
    Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
    Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.
    Zordoky BN; Anwar-Mohamed A; Aboutabl ME; El-Kadi AO
    Toxicol Appl Pharmacol; 2010 Jan; 242(1):38-46. PubMed ID: 19796650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes.
    Akimoto H; Bruno NA; Slate DL; Billingham ME; Torti SV; Torti FM
    Cancer Res; 1993 Oct; 53(19):4658-64. PubMed ID: 8402643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets.
    Sardão VA; Oliveira PJ; Holy J; Oliveira CR; Wallace KB
    Cell Biol Toxicol; 2009 Jun; 25(3):227-43. PubMed ID: 18386138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity.
    Pearlman M; Jendiroba D; Pagliaro L; Keyhani A; Liu B; Freireich EJ; Travis E
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):477-81. PubMed ID: 12827292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity.
    Zhu J; Zhang J; Zhang L; Du R; Xiang D; Wu M; Zhang R; Han W
    Biomed Pharmacother; 2011 Oct; 65(7):481-5. PubMed ID: 22000485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios.
    Dorr RT; Bozak KA; Shipp NG; Hendrix M; Alberts DS; Ahmann F
    Cancer Res; 1988 Sep; 48(18):5222-7. PubMed ID: 3409247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
    Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cyclic strain on embryonic stem cell-derived cardiomyocytes.
    Gwak SJ; Bhang SH; Kim IK; Kim SS; Cho SW; Jeon O; Yoo KJ; Putnam AJ; Kim BS
    Biomaterials; 2008 Mar; 29(7):844-56. PubMed ID: 18022225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
    Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.